pSivida microdrug patent paves way for Medidur
07 June, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) has received a US patent for a new microdrug delivery device which will be used with its Medidur implant, an injectable, sustained-release drug delivery system.
New WA AusBiotech industry development officer appointed
07 June, 2012 by AusBiotechAusBiotech members in Western Australia (WA) this week welcome the appointment of a new industry development officer (IDO), Michelle Nicolson to support the work of the WA Branch Committee.
BioDiem sets sights on dengue fever vaccine
07 June, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has been granted a license for vaccine technology developed at ANU with applications for diseases including dengue fever.
AHG files for CE Mark for heart patch
05 June, 2012 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has lodged an application for a CE Mark for CardioCel, the cardiovascular patch developed by subsidiary Celxel.
Phosphagenics to use new adhesive for pain patch
05 June, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) said in vitro tests of new adhesives in its TPM/oxycodone patch show superior performance to that developed by patch partner 3M.
NSW government to commit additional $70m to bolster health and medical research
05 June, 2012 by Tim DeanThe NSW government has responded to the NSW Health and Medical Research Strategic Review 2012 by committing $70 million to implement many of the report’s recommendations.
MoU to boost Hong Kong cooperation with AusBiotech
05 June, 2012 by AusBiotechA memorandum of understanding (MOU) between AusBiotech and the Hong Kong Biotechnology Organisation (HKBIO) is expected to boost cooperation between Hong Kong and Australia.
Starpharma hits 60% enrolment in BV trials
04 June, 2012 by Dylan Bushell-EmblingLess than three months after Starpharma (ASX:SPL) started recruiting patients for trials of VivaGel as a bacterial vaginosis treatment, enrolment levels have reached 60%.
Bionomics anticancer compound well tolerated
01 June, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) will use this week's ASCO meeting to present results of trials showing that the phase II dose level of BNC105 is safe and well-tolerated.
New York investment mission makes final preparations
31 May, 2012 by AusBiotechAusBiotech is about to host the ‘Australian Life Science Investment Showcase: New York 2012’ prior to the BIO 2012 convention (Boston).
Immuron progressing product pipeline
31 May, 2012 by Dylan Bushell-EmblingImmuron's (ASX:IMC) top leadership has acknowledged the company's flagging share price, but believe it does not reflect progress made developing two new products.
Terry White to stock Cellmid hair growth line
31 May, 2012 by Dylan Bushell-EmblingTerry White Chemists has become first pharmacy chain to agree to stock the Evolis hair growth product developed by Cellmid subsidiary Advangen.
Phylogica hits new milestone in Pfizer project
31 May, 2012 by Dylan Bushell-EmblingPerth-based Phylogica (ASX:PYC) will soon receive the second milestone payment in its peptide drug discovery collaboration with Pfizer.
Mark Harvey to focus on driving life science investment with AusBiotech
31 May, 2012 by Tim DeanAusBiotech’s newest board member, Dr Mark Harvey, aims to help drive investment into Australia’s life science sector.
Comment: Patent cliff revenues fertilise generics companies
31 May, 2012 by Staff WritersPharmaceutical companies might be scrambling, but the patent cliff is a boon for generics manufacturers around the world, says GlobalData’s Dr Jerry Isaacson
